Diana Bello-Roufai

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2023 · 50 citations

Cancer Management, Immunology, Pathology +18

Use of Pretreatment Perfusion MRI–based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy

Toulsie Ramtohul, Victoire Lepagney, Claire Bonneau et al. · Radiology · 2024 · 28 citations

Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)

Félix Blanc‐Durand, Claudia Lefeuvre‐Plesse, Isabelle Ray‐Coquard et al. · Gynecologic Oncology · 2020 · 20 citations

Medicine, Hypercalcemic Type, Gynecology +8

Clinico-pathological factors predicting pathological response in early triple-negative breast cancer

Clara Helal, Lounes Djerroudi, Toulsie Ramtohul et al. · npj Breast Cancer · 2025 · 19 citations · Full text

Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study

Mony Chenda Morisse, Nelly Étienne-Selloum, Diana Bello-Roufai et al. · Journal of Neuro-Oncology · 2019 · 13 citations

Neuro-oncology, Oncology, Multicentric Retrospective Study +9